

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Szardenings *et al.*

Appl. No. 09/674,733
(U.S. Natl. Phase of PCT/GB99/01388)

Int'l Filing Date: May 5, 1999

For: **Melanocortin 1 Receptor
Selective Compounds**

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 1085.0050000/RWE/ALS

**Amendment and Submission of Substitute Sequence Listing
Under 37 C.F.R. § 1.825(a)**

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.825(a), Applicants submit substitute sheets to amend the paper copy of the Sequence Listing.

In the Specification:

Please cancel the existing Sequence Listing for the above-identified application, replace it with the substitute Sequence Listing appended hereto, and insert the same at the end of the application.

Remarks


Applicants' Agent hereby states that the change made in the sequence listing does not include new matter. Applicants' undersigned Agent has amended the specification only to direct the entry of this corrected Sequence Listing at the end of the application.

In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

It is respectfully believed this application is now in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Aaron L. Schwartz
Agent for Applicants
Provisional Registration No. P-48,181

Date: 6/12/01

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600